ClinicalTrials.gg
CompletedNCT04451226Moonlight 3Updated Jan 31, 2025

A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause

A Phase 3 interventional study of Fezolinetant in Hot Flashes, sponsored by Astellas Pharma China, Inc.. Completed at 29 sites in China. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-31.

Sponsored by Astellas Pharma China, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing fezolinetant in Hot Flashes — 4 open to participants now, 5 under way, 4 of them phase 3. fezolinetant · Hot Flashes.

Enrollment
11th of 16
150 · median 249
Started
2020
with 1 other
Phase 3
10 of 16
2 open now
Registered
6th of 16
by date
Lead sponsor
2 of 16
Astellas Pharma China, Inc.

Among the 16 studies testing fezolinetant in Hot Flashes, this one is the 11th largest by enrollment, is one of 2 that started in 2020, is one of 10 in phase 3, and was the 6th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

4 of the 16 studies testing fezolinetant in Hot Flashes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fezolinetant

fezolinetant: first FDA approval 2023 (VEOZAH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing fezolinetant in Hot Flashes, or all of them as a file.
02

Study summary

This study is for women in menopause with hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life. The purpose of this study is to find out how safe it is for these women to take fezolinetant long term (up to 52 weeks). To do that, the study will look at the number and severity of the "adverse events." Those are the side effects that study participants have while they are in the study. The study treatment is fezolinetant (1 tablet of fezolinetant) once a day. The study participants will take study treatment for 52 weeks. At weeks 2 and 4 and then once a month, the study participants will go the hospital or clinic for a check-up. They will be asked about medications, side effects and how they feel. Other checks will include physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine will be collected for laboratory tests. At some study visits, study participants will complete questionnaires that are about their quality of life. Study participants who still have their uterus will have 2 more tests done at the first and last study visits. One of the 2 tests is endometrial biopsy. This test involves removing a small amount of tissue from the inside lining of the uterus. The tissue is then checked under a microscope. The other test is transvaginal ultrasound. It uses sound waves to create pictures of the organs in the pelvis. The sound waves are transmitted by a probe (transducer), which is placed inside the vagina. Study participants may have a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not have this test done in the last 12 months will have it done at the first study visit. They will have it done at the last study visit if they are due for their screening mammogram and their own doctor agrees. The last check-up at the hospital or clinic will be 3 weeks after the last dose of study treatment.

Read the detailed description

The study will consist of a screening period, a 52-week treatment period and a follow-up visit, 3 weeks after the last dose of study drug.

03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • Vasomotor Symptoms
  • menopause
  • fezolinetant
  • ESN364
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a ≥ 16 kg/m\^2 and ≤ 38 kg/m\^2 at the screening visit.
  • Subject confirmed as menopausal per 1 of the following criteria at the screening visit:

O Subject has spontaneous amenorrhea for >= 12 consecutive months O Spontaneous amenorrhea for ≥ 6 months with biochemical criteria of menopause (follicle-stimulating hormone [FSH] > 40 International Units per Liter [IU/L], or O Having had bilateral oophorectomy ≥ 6 weeks prior to the screening visit (with or without hysterectomy).

O FSH > 40 IU/L if subjects received hysterectomy but still have ovary

  • Subject is seeking treatment for relief for VMS associated with menopause.
  • Subject is in good general health as determined on the basis of medical history and general physical examination, including a bimanual clinical pelvic examination and clinical breast examination devoid of relevant clinical findings, performed at the screening visit; hematology and biochemistry parameters; pulse rate and/or blood pressure; and within the reference range for the population studied, or showing no deviations.
  • Subject has documentation of a normal/negative or no clinically significant abnormal findings on mammogram (or echo) (e.g., \<BI-RADS class 4; obtained at screening or within the prior 12 months of screening). Appropriate documentation includes a written report or an electronic report indicating normal/negative or no clinically significant abnormal findings.
  • Subject is willing to undergo a transvaginal ultrasound (TVU) to evaluate the uterus and ovaries at screening and at week 52 (end of treatment). For subjects who are withdrawn from the study prior to completion, a TVU should be collected at the early discontinuation (ED) visit. This is not required for subjects who have had a partial (supra-cervical) or full hysterectomy.
  • Subject is willing to undergo an endometrial at screening and at week 52 (end of treatment) or the ED visit if endometrial thickness > 4 millimeter (mm) indicated by TVU; and subject is willing to undergo an endometrial biopsy at any time during the study in the case of uterine bleeding. This is not required for subjects who have had a partial (supra-cervical) or full hysterectomy. A biopsy with insufficient material for evaluation, or unevaluable material, is acceptable provided the endometrial thickness is no greater than 8 mm.
  • Subject has documentation of a normal or not clinically significant abnormal Papanicolaou (Pap) test (or equivalent cervical cytology) within the previous 12 months of screening or at screening. This is not required for subjects who have had a full hysterectomy.
  • Subject has a negative urine pregnancy test at screening.
  • Subject has a negative serology panel (including virus surface antigen [HBs] and virus antibody [anti-HCV], and [HIV]) at screening.
  • Subject agrees not to participate in another interventional study while participating in the present study.

Exclusion criteria

Exclusion Criteria:

  • Subject uses a prohibited therapy (strong and moderate cytochrome P450 [CYP] 1A2 inhibitors, hormone replacement therapy [HRT], hormonal , any treatment for VMS [prescription, over the counter or herbal]) or is not willing to wash out and discontinue such drugs for the full extent of the study.
  • Subject has a known substance abuse or alcohol addiction within 6 months of screening.
  • Subject has a history of a malignant tumor, except for non- basal cell carcinoma of the skin.
  • Subject has uncontrolled hypertension, defined as systolic blood pressure >= 140 millimeters of mercury (mmHg) or diastolic blood pressure as >= 90 mmHg based on an average of 2 to 3 readings within the screening period.

O Subjects with a medical history of hypertension who are well controlled may be enrolled.

O Subjects who do not meet the criteria may, be re-assessed after initiation or review of antihypertensive measures.

  • Subject has a history of severe allergy, , or intolerance to drugs in general, including the study drug and any of its .
  • For subjects with a uterus: Subject has an unacceptable result from the TVU assessment at screening, i.e., full length of endometrial cavity cannot be visualized or presence of a abnormal finding.
  • For subjects with an endometrial thickness > 4 mm as indicated by TVU at screening: Subject has an endometrial confirming presence of disordered proliferative endometrium, endometrial hyperplasia, endometrial cancer, or other clinically significant abnormal findings in the at screening. A biopsy with insufficient material for evaluation, or unevaluable material is acceptable provided the endometrial thickness is no greater than 8 mm.
  • Subject has a history of an undiagnosed uterine bleeding within the last 6 months of screening.
  • Subject has a history of seizures or other convulsive disorders.
  • Subject has a medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine, or gynecological disease) or that could confound interpretation of the study outcome.
  • Subject has active liver disease, jaundice, or elevated liver aminotransferases ( [ALT] or aspartate aminotransferase [AST]), elevated total or direct , elevated (INR), or elevated alkaline phosphatase (ALP) at screening. Subject with mildly elevated ALT or AST up to 1.5 × the (ULN) can be enrolled if total and direct bilirubin are normal. Subject with mildly elevated ALP (up to 1.5 × ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Subject with Gilbert's syndrome with elevated total bilirubin (TBL) may be enrolled as long as hemolysis is ruled out (i.e., direct bilirubin (DBL), and reticulocytes are normal).
  • Subject has creatinine > 1.5 × ULN; or estimated (eGFR) using the Modification of Diet in Renal Disease formula \<= 59 milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2) at the screening visit.
  • Subject has a history of suicide attempt or suicidal behavior within the prior to 12 months of study enrollment or has suicidal ideation within the prior to 12 months of study enrollment (a response of "yes" to questions 4 or 5 on the suicidal ideation portion of the C-SSRS), or who is at significant risk to commit suicide at screening and at visit 2.
  • Subject has previously been enrolled in a clinical trial with fezolinetant.
  • Subject has received an study drug within 28 days or 5 half-lives, whichever is longer, prior to screening.
  • Subject is unable or unwilling to complete the study procedures.
  • Subject has any condition which, makes the subject unsuitable for study participation.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Fezolinetant

    Participants will receive fezolinetant 30 milligrams (mg) orally once daily for 52 weeks.

    Drug: Fezolinetant

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to 55 weeks

  2. Number of Participants With Adverse Events Based on Severity

    An AE is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to 55 weeks

Secondary outcomes

  1. Change From Baseline in Endometrial Thickness

    Endometrial thickness is a measure of how thick the lining of the uterus is. Change from baseline will be reported.

    Time frame: Baseline and 52 weeks

  2. Percentage of Participants With Endometrial Hyperplasia and/or Endometrial Cancer

    Endometrial hyperplasia is thickening of the lining of the uterus. Endometrial cancer is cancer of the lining of the uterus. Percentage of participants will be reported.

    Time frame: Up to 52 weeks

  3. Number of Participants With Vital Sign Abnormalities and/or Adverse Events (AEs)

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to 55 weeks

  4. Number of Participants With Laboratory Value Abnormalities and/or Adverse Events (AEs)

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to 55 weeks

  5. Number of Participants With Suicidal Ideation and/or Behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)

    The Columbia-Suicide Severity Rating Scale (C-SSRS) is a clinician administered assessment tool that evaluates suicidal ideation and behavior. Number of participants that have an affirmative response provided to the 5 items for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods (not plan) without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and/or to the 5 items for suicidal behavior (1. Preparatory acts or behavior, 2. Aborted attempt, 3. Interrupted attempt, 4. Actual attempt, 5. Completed suicide) will be reported.

    Time frame: Up to 55 weeks

  6. Number of Participants With Electrocardiogram (ECG) Abnormalities and/or Adverse Events (AEs)

    Number of participants with potentially clinically significant ECG values.

    Time frame: Up to 52 weeks

  7. Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) Levels

    Change from baseline in serum concentrations of BSAP will be reported.

    Time frame: Baseline, week 52 and week 55

  8. Change From Baseline in Procollagen Type 1 Amino-terminal Propeptide (P1NP) Levels

    Change from baseline in serum concentrations of P1NP will be reported.

    Time frame: Baseline, week 52 and week 55

  9. Change From Baseline in Carboxy-terminal Telopeptide of Type I Collagen (CTX) Levels

    Change from baseline in serum concentrations of CTX will be reported.

    Time frame: Baseline, week 52 and week 55

  10. Change From Baseline in Serum Concentration of Sex Hormones

    Change from baseline in serum concentration of sex hormones will be reported.

    Time frame: Baseline, week 4, week 12, week 24 , week 52 and week 55

  11. Change From Baseline in Sex Hormone-Binding Globulin (SHBG)

    Change from baseline in serum concentration of SHBG will be reported.

    Time frame: Baseline, week 4, week 12, week 24 , week 52 and week 55

  12. Pharmacokinetics (PK) of Fezolinetant in Plasma: Concentration

    Concentration will be recorded from the PK plasma samples collected.

    Time frame: Week 4, week 12, week 24 and week 52

  13. Pharmacokinetics (PK) of Fezolinetant Metabolite ES259564 in Plasma: Concentration

    Concentration will be recorded from the PK plasma samples collected.

    Time frame: Week 4, week 12, week 24 and week 52

07

Study locations

29 sites
  • Site CN86002
    Beijing, China
  • Site CN86015
    Beijing, China
  • Site CN86029
    Beijing, China
  • Site CN86032
    Chengdu, China
  • Site CN86001
    Guangzhou, China
  • Site CN86019
    Guangzhou, China
  • Site CN86022
    Guangzhou, China
  • Site CN86040
    Guangzhou, China
  • Site CN86042
    Guangzhou, China
  • Site CN86008
    Hangzhou, China
  • Site CN86012
    Hangzhou, China
  • Site CN86005
    Hunan, China
  • Site CN86039
    Jiangsu, China
  • Site CN86010
    Jinlin, China
  • Site CN86020
    Kunming, China
  • Site CN86037
    Liuzhou, China
  • Site CN86006
    Nanjing, China
  • Site CN86007
    Nanjing, China
  • Site CN86018
    Nanning, China
  • Site CN86034
    Ningxia Hui Nationality Autonomous Region, China
  • Site CN86009
    Shanghai, China
  • Site CN86011
    Shanxi, China
  • Site CN86004
    Shenzhen, China
  • Site CN86028
    Shijiazhuang, China
  • Site CN86026
    Suzhou, China
  • Site CN86038
    Taiyuan, China
  • Site CN86030
    Tianjin, China
  • Site CN86036
    Tianjin, China
  • Site CN86025
    Wuhan, China
08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Jun 2022, 22 months.

Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2020
First posted
Jun 30, 2020
StartActual
Jul 30, 2020
Primary completionActual
Jun 13, 2022
CompletionActual
Jun 13, 2022
Last update
Jan 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04451226
Responsible party
Sponsor
First posted
Jun 30, 2020
Start date
Jul 30, 2020
Primary completion
Jun 13, 2022
Completion
Jun 13, 2022
Last update
Jan 31, 2025

Study contacts

Medical Director
study director · Astellas Pharma China, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fezolinetant

Start the discussion